Promising therapeutic options in triple-negative breast cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and high risk of recurrence.
• TNBC is characterized by high grade, absence of hormone receptors and HER-2 negativity, high Ki-67 staining, and epithelial growth factor receptor (EGFR) expression, limiting treatment to cytotoxic chemotherapy.
• Shared molecular defects with BRCA1-associated breast cancer suggest potential therapeutic vulnerabilities in TNBC.

Purpose of the Study:

• To review current and future treatment strategies for triple-negative breast cancer (TNBC).
• To explore the potential of novel targeted agents and combination therapies in managing TNBC.
• To discuss the theoretical basis for combining poly-(ADP-ribose)-polymerase (PARP) inhibitors with DNA-damaging agents in TNBC.

Main Methods:

• Literature review of current and emerging treatment approaches for TNBC.
• Analysis of molecular characteristics of TNBC relevant to targeted therapies.
• Discussion of ongoing clinical trials involving targeted agents and chemotherapeutic combinations.

Main Results:

• Limited treatment options for TNBC currently rely on cytotoxic chemotherapy.
• The combination of PARP inhibitors with DNA-damaging agents (alkylating agents, topoisomerase I inhibitors) is theoretically promising for TNBC.
• Various targeted approaches are under investigation in clinical trials for TNBC, alone or with chemotherapy.

Conclusions:

• Novel targeted agents offer potential for improved TNBC treatment outcomes.
• Combination therapies, particularly PARP inhibitors with DNA-damaging drugs, warrant further investigation in TNBC.
• Ongoing clinical trials are crucial for advancing TNBC therapeutic strategies.